Japan-based Astellas Pharma has partnered with Proteostasis Therapeutics for research, development and commercialisation of therapies, which modulate the unfolded protein response (UPR).

Under the deal, Proteostasis’ Disease Relevant Translation (DRT) and Proteostasis Network platform will be used to develop therapies.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As part of the agreement, Proteostasis will receive an initial upfront payment from Astellas and also securities investment.

Proteostasis Therapeutics president Meenu Chhabra said: "Our novel approach to drug discovery, coupled with Astellas’ track record in drug development, will enable rapid discovery and development of therapies for important unmet medical needs."

"The partnership will concentrate on one genetic disease, and further explore additional indications, which can be affected through modulation of the UPR pathway."

Proteostasis will receive total payments of $400m, based on the achievement of future development and commercial milestones, as well as in the form of a research fund. It is also eligible to receive tiered royalties.

See Also:

Astellas was provided with an option to begin two additional projects under the same terms. If the right is fully exercised, value of the collaboration will be nearly $1.2bn.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Initially, the partnership will concentrate on one genetic disease, and further explore additional indications, which can be affected through modulation of the UPR pathway.

The firms will carry out discovery, screening and preclinical research to identify lead compounds for clinical development, as part of the deal.

Astellas senior vice-president Kenji Yasukawa said: "Proteostasis Therapeutics has a novel platform that offers a differentiated approach to discovering drugs for unmet medical needs."